Last updated: March 27, 2026
What is the product associated with NDC 35573-0439?
NDC 35573-0439 corresponds to Ciltacabtagene Autoleucel (Carvykti), a CAR-T cell therapy developed by Janssen and Legend Biotech for the treatment of relapsed or refractory multiple myeloma.
Market Overview
Indications and Approved Status
- Approved in multiple jurisdictions, including the US (FDA, February 2022).
- Indicated for adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.
Market Size
- Multiple myeloma accounts for approximately 1-2% of all cancers.
- New diagnoses in US: approximately 34,000 annually (per American Cancer Society, 2022).
- Estimated eligible patient population for CAR-T therapy: 15-20% of multiple myeloma patients.
- US market potential: 5,100–6,800 patients annually.
Competitive Landscape
- Other CAR-T therapies: idecabtagene vicleucel (Abecma), bb2121.
- Conventional therapies still dominate many treatment lines.
- Monoclonal antibodies (e.g., daratumumab), proteasome inhibitors, and immunomodulators remain standard, limiting immediate market penetration.
Price Points and Reimbursement
Listing Price
- Carvykti has a wholesale acquisition cost (WAC) of approximately \$425,000 per treatment cycle in the US.
- This price aligns with other CAR-T products, reflecting manufacturing costs, complexity, and indication.
Reimbursement and Cost Coverage
- Reimbursement hinges on coding and hospital coverage.
- Medicare and private insurers typically reimburse based on Diagnosis-Related Group (DRG) or specific billing codes (CPT codes).
Cost Factors Influencing Price Stability
- Manufacturing complexity and personalized nature increase costs.
- Supply chain stability affects pricing.
- Competition's pricing strategies may impact future pricing adjustments.
Price Projections and Market Trends
| Year |
Estimated Annual Sales |
Key Drivers |
Assumptions |
| 2023 |
\$300 million |
Ramp-up phase, limited coverage |
1,000–1,500 treated patients, initial uptake based on approvals |
| 2024 |
\$600 million |
Growing adoption |
Expanded provider networks, increased awareness |
| 2025 |
\$1 billion |
Standard treatment option |
Full reimbursement cycles, stable manufacturing costs |
| 2026+ |
\$1.2–\$1.5 billion |
Market saturation, competition |
Competition from other therapies, pricing adjustments |
Influences on Cost Dynamics
- Entry of biosimilar or alternative therapies could pressure prices downward from peak levels.
- Manufacturing efficiencies and new logistical solutions may decrease per-unit costs over time.
- Policy changes, such as value-based pricing or price caps, could modify reimbursement rates.
Regulatory and Policy Impact on Price
- Ongoing policy debates focus on drug pricing transparency and affordability.
- International markets regulate prices more aggressively, impacting global revenue potential.
- US agencies may enforce price negotiation provisions (cost-effectiveness analysis under Medicare negotiations).
Key Takeaways
- The initial price for Carvykti is approximately \$425,000 per treatment course.
- Market size is limited to relapsed/refractory multiple myeloma patients, with a potential U.S. market of around 6,800 annually.
- Sales are projected to reach \$1 billion by 2025, driven by increased adoption.
- Competitive pressures and policy changes could influence future pricing strategies.
- Cost reductions from manufacturing efficiencies are likely over the next few years.
FAQs
Q1: How does the price of NDC 35573-0439 compare to other CAR-T therapies?
A1: It is comparable; for example, Abecma (idecabtagene vicleucel) has a list price of approximately \$419,500 in the US.
Q2: What factors could reduce the treatment price in the future?
A2: Increased manufacturing efficiencies, market competition, and policy-driven price regulation.
Q3: What is the primary driver of revenue for this drug?
A3: The number of patients with relapsed/refractory multiple myeloma eligible and willing to receive CAR-T therapy.
Q4: Are there cost reductions post-approval?
A4: Possibly, through manufacturing scale-up, logistical improvements, and volume discounts.
Q5: How does reimbursement context impact pricing?
A5: Reimbursement depends on coding and insurer agreements, influencing the net revenue per treatment.
References
- American Cancer Society. (2022). Cancer facts & figures 2022.
- FDA. (2022). Biologics License Application Approval for Carvykti.
- IQVIA. (2023). Top 10 Oncology Drugs by Sales.
- Medicare. (2023). Billing and reimbursement codes for CAR-T therapy.
- EvaluatePharma. (2023). Global Oncology Market Forecasts.
